59
Views
5
CrossRef citations to date
0
Altmetric
Perspectives

Is there an anti-adenoviral drug on the horizon?

Pages 427-435 | Published online: 09 Jan 2014

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Rebecca MT Dang, Kathleen Watt & Alex Hui. (2021) Povidone iodine for the treatment of adenoviral conjunctivitis. Clinical and Experimental Optometry 104:3, pages 308-314.
Read now

Articles from other publishers (4)

Eric G. Romanowski, Kathleen A. Yates & Y. Jerold Gordon. (2023) Cyclopentenylcytosine (CPE-C): In Vitro and In Vivo Evaluation as an Antiviral against Adenoviral Ocular Infections. Molecules 28:13, pages 5078.
Crossref
Helga Rübsamen‐Schaeff & Helmut BuschmannPeter Lischka. 2022. New Drug Development for Known and Emerging Viruses. New Drug Development for Known and Emerging Viruses 277 296 .
Eric G. Romanowski, Kathleen A. Yates, Jeremy R. A. Paull, Graham P. Heery & Robert M. Q. Shanks. (2021) Topical Astodrimer Sodium, a Non-Toxic Polyanionic Dendrimer, Demonstrates Antiviral Activity in an Experimental Ocular Adenovirus Infection Model. Molecules 26:11, pages 3419.
Crossref
Eric G. RomanowskiKathleen A. YatesRobert M.Q. ShanksRegis P. Kowalski. (2019) Benzalkonium Chloride Demonstrates Concentration-Dependent Antiviral Activity Against Adenovirus In Vitro . Journal of Ocular Pharmacology and Therapeutics 35:5, pages 311-314.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.